A Prognostic Model of Bladder Cancer Based on Metabolism-Related Long Non-Coding RNAs

Abstract

BackgroundSome studies have revealed a close relationship between metabolism-related genes and the prognosis of bladder cancer. However, the relationship between metabolism-related long non-coding RNAs (lncRNA) regulating the expression of genetic material and bladder cancer is still blank. From this, we developed and validated a prognostic model based on metabolism-associated lncRNA to analyze the prognosis of bladder cancer.MethodsGene expression, lncRNA sequencing data, and related clinical information were extracted from The Cancer Genome Atlas (TCGA). And we downloaded metabolism-related gene sets from the human metabolism database. Differential expression analysis is used to screen differentially expressed metabolism-related genes and lncRNAs between tumors and paracancer tissues. We then obtained metabolism-related lncRNAs associated with prognosis by correlational analyses, univariate Cox analysis, and logistic least absolute shrinkage and selection operator (LASSO) regression. A risk scoring model is constructed based on the regression coefficient corresponding to lncRNA calculated by multivariate Cox analysis. According to the median risk score, patients were divided into a high-risk group and a low-risk group. Then, we developed and evaluated a nomogram including risk scores and Clinical baseline data to predict the prognosis. Furthermore, we performed gene-set enrichment analysis (GSEA) to explore the role of these metabolism-related lncRNAs in the prognosis of bladder cancer.ResultsBy analyzing the extracted data, our research screened out 12 metabolism-related lncRNAs. There are significant differences in survival between high and low-risk groups divided by the median risk scoring model, and the low-risk group has a more favorable prognosis than the high-risk group. Univariate and multivariate Cox regression analysis showed that the risk score was closely related to the prognosis of bladder cancer. Then we established a nomogram based on multivariate analysis. After evaluation, the modified model has good predictive efficiency and clinical application value. Furthermore, the GSEA showed that these lncRNAs affected bladder cancer prognosis through multiple links.ConclusionsA predictive model was established and validated based on 12 metabolism-related lncRNAs and clinical information, and we found these lncRNA affected bladder cancer prognosis through multiple links.

Identification of platinum resistance-related gene signature for prognosis and immune analysis in bladder cancer

“…Three independent prognostic factors were identified: age, stage, and risk score. As previously reported, age and stage are prominent risk factors for multiple tumors, including bladder Frontiers in Genetics frontiersin.org cancer (Hu et al, 2022;Lu et al, 2022). Further comparison showed that the model's prediction performance is superior to age and stage, demonstrating its high predictive power.…”

Novel LncRNA LINC02936 Suppresses Ferroptosis and Promotes Tumor Progression by Interacting with SIX1/CP Axis in Endometrial Cancer

“…Moreover, lncRNA HEPFAL contributes ferroptosis and suppresses tumor progression by affecting SLC7A11 ubiquitination in hepatocellular carcinoma 50 . LINC00239 suppresses ferroptosis and promotes cancer progression in colorectal cancer by interacting with Keap1 to stabilize Nrf2 51 . Although lncRNA are abnormally expressed in EC and are closely correlated to tumor development and chemotherapy resistance 52 , no studies have reported on lncRNAs promoting EC progression by regulating ferroptosis.…”

Predicting prostate cancer progression with a Multi-lncRNA expression-based risk score and nomogram integrating ISUP grading

“…Due to their specific expression and biological functions, there is growing interest in these molecules as potential biomarkers. Several reports have investigated the utility of lncRNAs in the clinical setting, and proposed that they can serve as biomarkers in liquid biopsies for diagnosis, monitoring disease progression and therapeutic response [ [20] , [21] , [22] , [23] , [24] ].…”